The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

An ever increasing amount of evidence strongly supports our position that drug-coated (-eluding) stents, when compared to bare-metal stents, significantly increase the risk of blood clot formation long after they are implanted in a patient. Heart attacks can be triggered from these blood clots. We are actively pursuing Boston Scientific Corporation (Taxus stent) and Cordis, a subsidiary of Johnson & Johnson (Cyper stents), the makers of these stents, who we believe will ultimately be held responsible for the harm these stents have caused.

If you have suffered complications, call us for a free consultation.

Patients who received drug-eluding stents are at substantially increased risk of potentially fatal blood clotting,

known as stent thrombosis, according to the findings of the Cleveland Clinic Foundation as reported by The American Journal of Medicine. Only three years since their introduction into the medical device market, drug-eluding stents have grown to command over 85% of the coronary stent market.

Boston Scientific Corporation is the largest manufacturer of heart stents throughout the United States. The drug-coated stents emit a drug called Paclitaxel, which is intended to inhibit restenosis caused by scar tissue growth. In November of 2006, it was found that the drug-eluding stents caused blood clots to form in patients up to five times more often than the original bare-metal stents.

Boston Scientific Corporation, previously voluntarily recalled its drug-eluding Taxus stent devices because of defects in the drug delivery system. Approximately 85,000 Taxus stents were involved in the recall. The Taxus drug-eluding stent has been linked to death and serious injuries.

Comments are closed.

Of Interest